Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ZNF207

Gene summary for ZNF207

Gene summary.

Gene information	Species	Human
	Gene symbol	ZNF207
	Gene ID	7756
	Gene name	zinc finger protein 207
	Gene Alias	BuGZ
	Cytomap	17q11.2
	Gene Type	protein-coding
	GO ID	GO:0000070
	UniProtAcc	O43670

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7756	ZNF207	GSM4909293	Human	Breast	IDC	2.64e-97	1.07e+00	0.1581
7756	ZNF207	GSM4909294	Human	Breast	IDC	3.97e-07	-2.86e-01	0.2022
7756	ZNF207	GSM4909296	Human	Breast	IDC	4.75e-18	-3.86e-01	0.1524
7756	ZNF207	GSM4909297	Human	Breast	IDC	3.00e-15	-2.38e-01	0.1517
7756	ZNF207	GSM4909298	Human	Breast	IDC	2.12e-02	-1.33e-01	0.1551
7756	ZNF207	GSM4909311	Human	Breast	IDC	9.94e-29	-4.10e-01	0.1534
7756	ZNF207	GSM4909312	Human	Breast	IDC	2.51e-09	-1.43e-01	0.1552
7756	ZNF207	GSM4909319	Human	Breast	IDC	3.00e-36	-4.07e-01	0.1563
7756	ZNF207	GSM4909320	Human	Breast	IDC	7.16e-05	-4.33e-01	0.1575
7756	ZNF207	GSM4909321	Human	Breast	IDC	1.77e-14	-2.41e-01	0.1559
7756	ZNF207	ctrl6	Human	Breast	Precancer	2.88e-02	2.83e-01	-0.0061
7756	ZNF207	brca2	Human	Breast	Precancer	2.96e-02	1.37e-02	-0.024
7756	ZNF207	M1	Human	Breast	IDC	1.61e-15	5.62e-01	0.1577
7756	ZNF207	M2	Human	Breast	IDC	6.37e-05	2.32e-01	0.21
7756	ZNF207	NCCBC14	Human	Breast	DCIS	1.46e-04	-2.94e-01	0.2021
7756	ZNF207	NCCBC3	Human	Breast	DCIS	3.74e-02	-3.00e-02	0.1198
7756	ZNF207	NCCBC5	Human	Breast	DCIS	7.01e-07	-1.85e-01	0.2046
7756	ZNF207	P1	Human	Breast	IDC	1.14e-18	2.55e-01	0.1527
7756	ZNF207	P2	Human	Breast	IDC	1.19e-04	2.91e-01	0.21
7756	ZNF207	DCIS2	Human	Breast	DCIS	1.84e-62	1.66e-01	0.0085

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000734610	Esophagus	HGIN	regulation of mitotic cell cycle	98/2587	457/18723	4.39e-06	1.42e-04	98
GO:00447729	Esophagus	HGIN	mitotic cell cycle phase transition	89/2587	424/18723	2.80e-05	7.21e-04	89
GO:005125826	Esophagus	HGIN	protein polymerization	66/2587	297/18723	4.96e-05	1.19e-03	66
GO:19019906	Esophagus	HGIN	regulation of mitotic cell cycle phase transition	65/2587	299/18723	1.12e-04	2.36e-03	65
GO:00070527	Esophagus	HGIN	mitotic spindle organization	31/2587	120/18723	3.35e-04	5.50e-03	31
GO:01400146	Esophagus	HGIN	mitotic nuclear division	61/2587	287/18723	3.38e-04	5.55e-03	61
GO:00070593	Esophagus	HGIN	chromosome segregation	71/2587	346/18723	3.47e-04	5.62e-03	71
GO:19028507	Esophagus	HGIN	microtubule cytoskeleton organization involved in mitosis	36/2587	147/18723	3.61e-04	5.68e-03	36
GO:00070518	Esophagus	HGIN	spindle organization	42/2587	184/18723	6.07e-04	8.49e-03	42
GO:00459305	Esophagus	HGIN	negative regulation of mitotic cell cycle	49/2587	235/18723	1.88e-03	2.01e-02	49
GO:19019915	Esophagus	HGIN	negative regulation of mitotic cell cycle phase transition	39/2587	179/18723	2.31e-03	2.36e-02	39
GO:00903077	Esophagus	HGIN	mitotic spindle assembly	18/2587	65/18723	2.46e-03	2.45e-02	18
GO:00000703	Esophagus	HGIN	mitotic sister chromatid segregation	36/2587	168/18723	4.42e-03	3.87e-02	36
GO:19019876	Esophagus	HGIN	regulation of cell cycle phase transition	72/2587	390/18723	5.78e-03	4.70e-02	72
GO:014001414	Esophagus	ESCC	mitotic nuclear division	218/8552	287/18723	6.17e-26	1.78e-23	218
GO:0031647111	Esophagus	ESCC	regulation of protein stability	223/8552	298/18723	5.76e-25	1.52e-22	223
GO:000007011	Esophagus	ESCC	mitotic sister chromatid segregation	138/8552	168/18723	1.37e-22	2.63e-20	138
GO:00008194	Esophagus	ESCC	sister chromatid segregation	157/8552	202/18723	8.41e-21	1.33e-18	157
GO:003304416	Esophagus	ESCC	regulation of chromosome organization	145/8552	187/18723	3.80e-19	4.31e-17	145
GO:000705911	Esophagus	ESCC	chromosome segregation	238/8552	346/18723	1.72e-18	1.82e-16	238

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ZNF207

SNV

Missense_Mutation

c.157N>T

p.His53Tyr

p.H53Y

O43670

protein_coding

deleterious(0)

probably_damaging(0.969)

TCGA-A8-A094-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

novel

c.841N>A

p.Val281Ile

p.V281I

O43670

protein_coding

tolerated(0.31)

probably_damaging(0.971)

TCGA-EW-A6SD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

tch

ZNF207

insertion

Nonsense_Mutation

novel

c.1472_1473insCTAAATACTCGAA

p.Gly492Ter

p.G492*

O43670

protein_coding

TCGA-B6-A0IA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.715N>G

p.Gln239Glu

p.Q239E

O43670

protein_coding

tolerated(0.23)

benign(0.078)

TCGA-C5-A3HE-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.1300N>T

p.Met434Leu

p.M434L

O43670

protein_coding

deleterious_low_confidence(0.04)

benign(0.138)

TCGA-C5-A7CL-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

ZNF207

SNV

Missense_Mutation

novel

c.679C>T

p.Pro227Ser

p.P227S

O43670

protein_coding

tolerated(0.05)

possibly_damaging(0.457)

TCGA-VS-A8EK-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

ZNF207

SNV

Missense_Mutation

c.849N>G

p.Ser283Arg

p.S283R

O43670

protein_coding

deleterious(0.01)

benign(0.221)

TCGA-A6-2680-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

novel

c.265N>T

p.Asp89Tyr

p.D89Y

O43670

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-AA-3984-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.1433G>A

p.Arg478Gln

p.R478Q

O43670

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.947)

TCGA-CK-5916-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.974N>A

p.Ser325Asn

p.S325N

O43670

protein_coding

tolerated(0.37)

benign(0)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1